Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay
Identifieur interne : 004B19 ( Main/Exploration ); précédent : 004B18; suivant : 004B20Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay
Auteurs : D. Dressler [Royaume-Uni] ; G. Dirnberger [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] ; A. Irmer [Allemagne] ; N. P. Quinn [Royaume-Uni] ; H. Bigalke [Allemagne] ; C. D. Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2000-09.
English descriptors
- KwdEn :
- Animals, Anti-Dyskinesia Agents (immunology), Anti-Dyskinesia Agents (pharmacology), Anti-Dyskinesia Agents (therapeutic use), Antibodies, Bacterial (blood), Antibody Formation, Antibody testing, Bioassay, Biological Assay (methods), Botulinum Toxins, Type A (immunology), Botulinum Toxins, Type A (pharmacology), Botulinum Toxins, Type A (therapeutic use), Botulinum toxin therapy, Drug Resistance, Dystonic Disorders (drug therapy), Dystonic Disorders (immunology), Female, Humans, Male, Mice, Sensitivity and Specificity, Statistics, Nonparametric, Treatment Failure.
- MESH :
- chemical , blood : Antibodies, Bacterial.
- chemical , immunology : Anti-Dyskinesia Agents, Botulinum Toxins, Type A.
- chemical , pharmacology : Anti-Dyskinesia Agents, Botulinum Toxins, Type A.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins, Type A.
- drug therapy : Dystonic Disorders.
- immunology : Dystonic Disorders.
- methods : Biological Assay.
- Animals, Antibody Formation, Drug Resistance, Female, Humans, Male, Mice, Sensitivity and Specificity, Statistics, Nonparametric, Treatment Failure.
Abstract
Conventionally, the standard test for detection of antibodies against botulinum toxin (BT‐A) has been the mouse lethality assay (MLA). Because this test has a number of disadvantages, a novel mouse protection assay (MPA) was recently introduced. We sought to compare the results of both tests. Forty‐three samples from 38 patients with cervical dystonia and complete or partial subjective BT‐A therapy failure underwent simultaneous MPA and MLA testing. Twenty‐seven samples showed concordant results in both tests. Eleven of them were MPA‐ and MLA‐positive and 16 MPA‐ and MLA‐negative, resulting in a significant association of the dichotomous test results (Fisher exact test, p <0.01). Sixteen samples showed discordant results. All of those were MPA‐positive and MLA‐negative. This excess of MPA‐positive results was also significant (Wilcoxon signed‐rank test, p <0.001). Of the patients with MPA‐positive samples, 62% had complete and 38% had partial therapy failure. Of the patients with MLA‐positive samples, 90% had complete and 10% had partial therapy failure. MPA and MLA results show significant association. Statistical analysis and predominance of partial therapy failure in MPA‐positive patients demonstrate higher sensitivity of MPA. With its methodologic advantages, its test parameter being more relevant to BT‐A therapy, and its higher sensitivity, the MPA appears to be superior to the MLA.
Url:
DOI: 10.1002/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002964
- to stream Istex, to step Curation: 002964
- to stream Istex, to step Checkpoint: 003320
- to stream Main, to step Merge: 007417
- to stream PubMed, to step Corpus: 003E98
- to stream PubMed, to step Curation: 003E98
- to stream PubMed, to step Checkpoint: 004028
- to stream Ncbi, to step Merge: 000353
- to stream Ncbi, to step Curation: 000353
- to stream Ncbi, to step Checkpoint: 000353
- to stream Main, to step Merge: 007171
- to stream Main, to step Curation: 004B19
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay</title><author><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D." last="Dressler">D. Dressler</name></author><author><name sortKey="Dirnberger, G" sort="Dirnberger, G" uniqKey="Dirnberger G" first="G." last="Dirnberger">G. Dirnberger</name></author><author><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name></author><author><name sortKey="Irmer, A" sort="Irmer, A" uniqKey="Irmer A" first="A." last="Irmer">A. Irmer</name></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name></author><author><name sortKey="Bigalke, H" sort="Bigalke, H" uniqKey="Bigalke H" first="H." last="Bigalke">H. Bigalke</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:08B2CBDDC156BA07890AC39F566FF91BB2FD2921</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X</idno><idno type="url">https://api.istex.fr/document/08B2CBDDC156BA07890AC39F566FF91BB2FD2921/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002964</idno><idno type="wicri:Area/Istex/Curation">002964</idno><idno type="wicri:Area/Istex/Checkpoint">003320</idno><idno type="wicri:doubleKey">0885-3185:2000:Dressler D:botulinum:toxin:antibody</idno><idno type="wicri:Area/Main/Merge">007417</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11009207</idno><idno type="wicri:Area/PubMed/Corpus">003E98</idno><idno type="wicri:Area/PubMed/Curation">003E98</idno><idno type="wicri:Area/PubMed/Checkpoint">004028</idno><idno type="wicri:Area/Ncbi/Merge">000353</idno><idno type="wicri:Area/Ncbi/Curation">000353</idno><idno type="wicri:Area/Ncbi/Checkpoint">000353</idno><idno type="wicri:doubleKey">0885-3185:2000:Dressler D:botulinum:toxin:antibody</idno><idno type="wicri:Area/Main/Merge">007171</idno><idno type="wicri:Area/Main/Curation">004B19</idno><idno type="wicri:Area/Main/Exploration">004B19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay</title><author><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D." last="Dressler">D. Dressler</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Dirnberger, G" sort="Dirnberger, G" uniqKey="Dirnberger G" first="G." last="Dirnberger">G. Dirnberger</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Irmer, A" sort="Irmer, A" uniqKey="Irmer A" first="A." last="Irmer">A. Irmer</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Toxicology, Medizinische Hochschule, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bigalke, H" sort="Bigalke, H" uniqKey="Bigalke H" first="H." last="Bigalke">H. Bigalke</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Toxicology, Medizinische Hochschule, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-09">2000-09</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="973">973</biblScope><biblScope unit="page" to="976">976</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">08B2CBDDC156BA07890AC39F566FF91BB2FD2921</idno><idno type="DOI">10.1002/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X</idno><idno type="ArticleID">MDS1031</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Dyskinesia Agents (immunology)</term><term>Anti-Dyskinesia Agents (pharmacology)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Antibodies, Bacterial (blood)</term><term>Antibody Formation</term><term>Antibody testing</term><term>Bioassay</term><term>Biological Assay (methods)</term><term>Botulinum Toxins, Type A (immunology)</term><term>Botulinum Toxins, Type A (pharmacology)</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Botulinum toxin therapy</term><term>Drug Resistance</term><term>Dystonic Disorders (drug therapy)</term><term>Dystonic Disorders (immunology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Mice</term><term>Sensitivity and Specificity</term><term>Statistics, Nonparametric</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Bacterial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonic Disorders</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Dystonic Disorders</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biological Assay</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>Drug Resistance</term><term>Female</term><term>Humans</term><term>Male</term><term>Mice</term><term>Sensitivity and Specificity</term><term>Statistics, Nonparametric</term><term>Treatment Failure</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Conventionally, the standard test for detection of antibodies against botulinum toxin (BT‐A) has been the mouse lethality assay (MLA). Because this test has a number of disadvantages, a novel mouse protection assay (MPA) was recently introduced. We sought to compare the results of both tests. Forty‐three samples from 38 patients with cervical dystonia and complete or partial subjective BT‐A therapy failure underwent simultaneous MPA and MLA testing. Twenty‐seven samples showed concordant results in both tests. Eleven of them were MPA‐ and MLA‐positive and 16 MPA‐ and MLA‐negative, resulting in a significant association of the dichotomous test results (Fisher exact test, p <0.01). Sixteen samples showed discordant results. All of those were MPA‐positive and MLA‐negative. This excess of MPA‐positive results was also significant (Wilcoxon signed‐rank test, p <0.001). Of the patients with MPA‐positive samples, 62% had complete and 38% had partial therapy failure. Of the patients with MLA‐positive samples, 90% had complete and 10% had partial therapy failure. MPA and MLA results show significant association. Statistical analysis and predominance of partial therapy failure in MPA‐positive patients demonstrate higher sensitivity of MPA. With its methodologic advantages, its test parameter being more relevant to BT‐A therapy, and its higher sensitivity, the MPA appears to be superior to the MLA.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Basse-Saxe</li><li>Grand Londres</li></region><settlement><li>Hanovre</li><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D." last="Dressler">D. Dressler</name></region><name sortKey="Bhatia, K P" sort="Bhatia, K P" uniqKey="Bhatia K" first="K. P." last="Bhatia">K. P. Bhatia</name><name sortKey="Dirnberger, G" sort="Dirnberger, G" uniqKey="Dirnberger G" first="G." last="Dirnberger">G. Dirnberger</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name></country><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Irmer, A" sort="Irmer, A" uniqKey="Irmer A" first="A." last="Irmer">A. Irmer</name></region><name sortKey="Bigalke, H" sort="Bigalke, H" uniqKey="Bigalke H" first="H." last="Bigalke">H. Bigalke</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:08B2CBDDC156BA07890AC39F566FF91BB2FD2921
|texte= Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay
}}
| This area was generated with Dilib version V0.6.23. |  |